GlassScriptPhysician profile
Julia Ann Taylor
NPI 1336248129
$12,130.48
in general payments reported to CMS, 2019-2025
27 companies · $2,481 in 2025
The $2,481 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,456 · 2022: $1,794 · 2023: $2,483 · 2024: $3,917 · 2025: $2,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,418 · Consulting Fee: $1,063 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,418.23 |
| Consulting Fee | $1,062.50 |
| Education | $399.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,150.54 | 2021-2025 | |
| Janssen Biotech, INC. | $2,659.00 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $1,083.37 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $843.90 | 2021-2025 | |
| Amgen INC. | $628.30 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $587.70 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $533.24 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $490.98 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $400.74 | 2021-2025 | Dupixent, Libtayo |
| Allergan, INC. | $275.52 | 2021-2022 | |
| Merz North America, INC. | $246.70 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $179.19 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $147.21 | 2021-2025 | |
| Incyte Corporation | $136.77 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $132.32 | 2022-2023 | Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $127.67 | 2021-2022 | |
| Dermavant Sciences, INC. | $116.34 | 2022-2024 | Vtama |
| Biofrontera INC. | $91.93 | 2021-2025 | |
| Galderma Laboratories, L.P. | $86.96 | 2021-2025 | Nemluvio, Dysport |
| Genentech USA, INC. | $55.44 | 2023-2024 | Xolair |
| Genzyme Corporation | $42.05 | 2021-2023 | |
| Blueprint Medicines Corporation | $27.29 | 2025 | Ayvakit |
| Krystal Biotech INC | $22.61 | 2023 | Vyjuvek |
| Organon LLC | $22.15 | 2025 | Hadlima, Vtama |
| Organogenesis INC. | $17.52 | 2024 | |
| Arcutis Biotherapeutics, INC. | $14.36 | 2024 | Zoryve |
| Biowound Solutions, INC. | $10.68 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.